Defects in alternative splicing are frequently found in human tumors and result either from
mutations in splicing‐regulatory elements of specific cancer genes or from changes in the …

Simple Summary Overexpression of HER2 receptors have been identified in various types of
cancer including breast cancer and ovarian cancer. HER2 overexpression is generally …

HER2-positive breast cancer (HER2+ BC) represents 15–20% of all BCs. In the last two
decades, the introduction of monoclonal antibodies (MoAbs), tyrosine kinase inhibitors …

Emerging evidence indicates that gut microbiota affect the response to anticancer therapies
by modulating the host immune system. In this study, we investigated the impact of gut …

Simple Summary A proportion of breast tumors bear the oncogenic transmembrane tyrosine
kinase protein HER2. Even though therapies that target HER2 have changed the prognosis …

The gut microbiota's function in regulating health has seen it linked to disease progression
in several cancers. However, there is limited research detailing its influence in breast cancer …

Overexpression of human epidermal growth factor receptor-2 (HER2) occurs in 20–30% of
invasive breast cancers. Monoclonal antibody therapy is effective in treating HER2-driven …

Introduction Osimertinib is the current recommended treatment for EGFR T790M–positive
NSCLC after EGFR tyrosine kinase inhibitor therapy. However, resistance to osimertinib …

Through whole-transcriptome profiling of HER2+ breast carcinomas (BCs), we previously
showed that those sensitive to trastuzumab are addicted to this oncoprotein and are …

Simple Summary Breast cancer (BC) is not a single disease, but a group of different tumors,
and altered HER2 expression defines a particularly aggressive subtype. Although HER2 …